糖尿病类型与慢性并发症对提前退出劳动力市场的影响:芬兰糖尿病登记研究
该研究基于芬兰1998-2011年全国登记数据(1型糖尿病45,756人,2型糖尿病299,931人),分析提前退出劳动力市场(65岁前领取非老年养老金或死亡)的风险。1型糖尿病患者提前退出的中位年龄为54.0岁,2型为58.3岁,相差4.3年;1型患者提前退出者平均损失工作年数多6.0年,平均生产力成本高1.4倍;2型糖尿病提前退出事件的总生产力成本更高(144亿欧元 vs 28亿欧元)。
要点
- 1型糖尿病患者提前退出劳动力市场的中位年龄比2型早4.3年(54.0 vs 58.3岁)。
- 除眼相关并发症外,各糖尿病并发症均增加提前退出风险,且不因糖尿病类型而异。
- 1型提前退出者平均损失工作年数多6.0年,平均生产力成本高1.4倍。
核心结论
- 1型与2型糖尿病患者的提前退出劳动力市场风险模式存在显著差异,差异在接近法定退休年龄时最大。
- 1型糖尿病患者平均更早退出,导致平均损失工作年数和平均生产力成本更高。
- 预防、及时诊断和管理糖尿病对避免个体福祉和生产力损失具有重要潜力。
研究设计与样本
- 基于芬兰国家登记的开放队列研究,纳入1998-2011年17-64岁工作年龄糖尿病患者。
- 1型糖尿病45,756人,2型糖尿病299,931人;从登记库收集养老金、死亡、医疗使用、药物和人口学数据。
- 采用Kaplan-Meier法和扩展Cox回归模型分析提前退出及其风险因素,线性回归模型分析损失工作年数和生产力成本的风险因素。
主要发现
- 1型与2型糖尿病组提前退出劳动力市场的中位年龄分别为54.0岁和58.3岁,相差4.3年。
- 1型糖尿病患者40岁后提前退出风险增加速度快于2型糖尿病患者。
- 除眼相关并发症外,每种糖尿病并发症均与提前退出风险增加相关,且不因糖尿病类型而异。
- 糖尿病并发症部分但未完全解释1型和2型糖尿病之间的差异。
- 在提前退出者中,1型糖尿病组平均损失工作年数比2型糖尿病组多6.0年,平均生产力成本为2型糖尿病组的1.4倍。
关键数值与推荐
- 提前退出定义为65岁前开始领取非老年养老金或65岁前死亡。
- 1型糖尿病组提前退出事件的总生产力成本为2800百万欧元,2型糖尿病组为14,400百万欧元。
临床怎么用
- 内分泌科医生应关注糖尿病患者(尤其1型)的并发症预防和及时管理,以降低提前退出劳动力市场的风险。
- 针对1型糖尿病患者,需特别关注40岁后提前退出风险的加速上升,加强职业健康支持。
- 并发症管理可能部分减少但无法完全消除1型和2型糖尿病之间提前退出的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Diabetes and diabetes complications are a cause of substantial morbidity, resulting in early exits from the labour force and lost productivity. The aim of this study was to examine differences in early exits between people with type 1 and 2 diabetes and to assess the role of chronic diabetes complications on early exit. We also estimated the economic burden of lost productivity due to early exits. METHODS: People of working age (age 17-64) with diabetes in 1998-2011 in Finland were detected using national registers (Ntype 1 = 45,756, Ntype 2 = 299,931). For the open cohort, data on pensions and deaths, healthcare usage, medications and basic demographics were collected from the registers. The outcome of the study was early exit from the labour force defined as pension other than old age pension beginning before age 65, or death before age 65. We analysed the early exit outcome and its risk factors using the Kaplan-Meier method and extended Cox regression models. We fitted linear regression models to investigate the risk factors of lost working years and productivity costs among people with early exit. RESULTS: The difference in median age at early exit from the labour force between type 1 (54.0) and type 2 (58.3) diabetes groups was 4.3 years. The risk of early exit among people with type 1 diabetes increased faster after age 40 compared with people with type 2 diabetes. Each of the diabetes complications was associated with an increase in the hazard of early exit regardless of diabetes type compared with people without the complication, with eye-related complications as an exception. Diabetes complications partly but not completely explained the difference between diabetes types. The mean lost working years was 6.0 years greater in the type 1 diabetes group than in the type 2 diabetes group among people with early exit. Mean productivity costs of people with type 1 diabetes and early exit were found to be 1.4-fold greater compared with people with type 2 diabetes. The total productivity costs of incidences of early exits in the type 2 diabetes group were notably higher compared with the type 1 group during the time period (€14,400 million, €2800 million). CONCLUSIONS/INTERPRETATION: We found a marked difference in the patterns of risk of early exit between people with type 1 and type 2 diabetes. The difference was largest close to statutory retirement age. On average, exits in the type 1 diabetes group occurred at an earlier age and resulted in higher mean lost working years and mean productivity costs. The potential of prevention, timely diagnosis and management of diabetes is substantial in terms of avoiding reductions in individual well-being and productivity.
引用
- Kurkela O, Forma L, Ilanne-Parikka P, et al. Association of diabetes type and chronic diabetes complications with early exit from the labour force: register-based study of people with diabetes in Finland. Diabetologia. 2021. PMID: 33475814. doi:10.1007/s00125-020-05363-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。